Article Information
History
- April 24, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Andrew S. Poklepovic1,*,
- Palak Shah1,
- Mary Beth Tombes2,
- Ellen Shrader2,
- Dipankar Bandyopadhyay3,
- Xiaoyan Deng3,
- Catherine H. Roberts2,
- Alison A. Ryan2,
- Daniel Hudson2,
- Heidi Sankala2,
- Maciej Kmieciak1,
- Paul Dent1,4,* and
- Mark G. Malkin5,*
- 1Departments of Internal Medicine, USA
- 2Massey Cancer Center, USA
- 3Biostatistics, USA
- 4Biochemistry and Molecular Biology, USA
- 5Neurology, Virginia Commonwealth University, Richmond, Virginia. USA
- ↵*Corresponding Authors: Mark G. Malkin, MD Andrew S. Poklepovic, MD Paul Dent, PhD
School of Medicine Virginia Commonwealth University Richmond, VA, 23298 andrew.poklepovic{at}vcuhealth.org
Posted April 24, 2024.
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma
